Efficacy and Safety of Lanreotide Autogel (ATG) in Combination With Temozolomide in Subjects With Thoracic Neuroendocrine Tumors.

Neuroendocrine Tumours Clinical Trial

— ATLANT  

Official title:

Efficacy and Safety of Lanreotide ATG 120 mg in Combination With Temozolomide in Subjects With Progressive Well Differentiated Thoracic Neuroendocrine Tumors. A Phase II, Multicentre, Single Arm, Open-label Trial.

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT02698410
• Other study ID #: A-93-52030-325
• Secondary ID: 2014-005579-10
• Status: Completed
• Phase: Phase 2
• Start date: July 2016
• Est. completion date: June 18, 2019

Study information

• Verified date: September 2020
• Source: Ipsen
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The purpose of the protocol is to evaluate the efficacy and safety of Lanreotide ATG 120 mg in combination with Temozolomide in subjects with unresectable advanced neuroendocrine tumours of the lung or thymus as Disease Control Rate at 9 months.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 40
• Est. completion date: June 18, 2019
• Est. primary completion date: February 8, 2019
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Histological documented unresectable advanced (locally or metastatic) well or moderately differentiated neuroendocrine tumors of the lung or thymus (typical and atypical carcinoids according to the World Health Organisation (WHO) 2004 criteria);

• Imaging documented progression within 12 months before screening visit (V1), according to RECIST criteria v 1.1;

• Measurable disease, as defined by RECIST criteria v 1.1, on a CT scan performed at screening visit (V1);

• Octreoscan or Ga68-DOTA-TATE/TOC/NOC-PET-TC within 12 months before screening visit (V1);

• Adequate liver, renal and bone marrow function.

Exclusion Criteria:

• Poorly differentiated neuroendocrine carcinoma and mixed Neuroendocrine tumours (NET), according to WHO 2004 criteria

• Neuroendocrine tumours other than lung or thymus

• Non-neuroendocrine thymic neoplasm

• Received a prior therapy with Peptide Receptor Radionuclide Therapy (PRRT) within 6 months prior to screening visit (V1)

• Treated with systemic therapies (chemotherapy, interferon-alpha, somatostatin analogues, molecular target therapies) within 1 month prior to screening visit (V1)

• Treated with a number of systemic therapy lines > 3 prior to screening visit (V1), and any of the following:

1. for chemotherapy no more than 1 line prior to V1

2. for somatostatin analogue no more than 1 line therapy, considered as treatment lasting more than 6 months, prior to V1 no therapy with Temozolomide (TMZ) prior to V1

3. Received a prior therapy with Peptide Receptor Radionuclide Therapy (PRRT) within 6 months prior to screening visit (V1)

• Received external palliative radiotherapy within the last 28 days prior to screening visit (V1)

• Received locoregional therapies (Transarterial embolization, Transcatheter arterial chemoembolization, thermo-ablation with radio-frequency) and Selective internal radiotherapy within 3 months prior to screening visit (V1)

• Presence of symptomatic brain metastasis

• Subjects with symptomatic cholelithiasis at screening visit (V1)

Related Conditions & MeSH terms

• Neuroendocrine Tumors
• Neuroendocrine Tumours

Intervention

Drug:
• Lanreotide (Autogel formulation) and Temozolomide

Locations

Country	Name	City	State
Italy	Unità Operativa di Oncologia Azienda Ospedaliera Spedali Civili di Brescia	Brescia
Italy	Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) S.r.l., IRCCS	Meldola
Italy	Unità Oncologia Medica Gastrointestinale e Tumori Neuroendocrini Istituto Europeo di Oncologia, IEO	Milan
Italy	Dipartimento di Endocrinologia e Oncologia Molecolare e Clinica , Università degli Studi	Napoli
Italy	Dipartimento di Oncologia Università di Torino Ospedale San Luigi Gonzaga	Orbassano
Italy	S.C di Oncologia Medica, Azienda Ospedaliera Universitaria di Perugia	Perugia
Italy	U.O. Oncologia - Azienda Ospedaliero-Universitaria Pisana Ospedale S. Chiara	Pisa
Italy	Oncologia Medica - Istituto Tumori Regina Elena San Gallicano	Roma
Italy	OUC di Oncologia- Azienda Ospedaliera Universitaria Integrata - Ospedale Borgo Roma	Verona
Italy	Oncologia Medica - Istituto Oncologico del Mediterraneo - IOM	Viagrande	Catania

Sponsors (1)

Lead Sponsor	Collaborator
Ipsen

Country where clinical trial is conducted

Italy, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Disease Control Rate (DCR) Assessed Locally at Month 9	Responders were participants who showed disease control according to Response Evaluation Criteria in Solid Tumors (RECIST) criteria v 1.1 assessed locally by the investigator. The DCR was defined as complete response (CR), partial response (PR) or stable disease (SD) according to RECIST criteria v1.1. A sensitivity analysis-1 of local DCR was performed excluding participants withdrawn before 9 months with reason other than progressive disease (PD) or missing assessment and considering participants with PD prior or at 9 months as failures. In addition, a sensitivity analysis-2 was performed in order to consider assessments done between 7.5 and 10.5 months as 9 months assessments when 9-month assessment was missing using same methodology, i.e. considering PD prior or at 9 months and participants withdrawn with other or missing reasons as failures.	Up to Month 9; for sensitivity analysis-2, up to 10.5 months
Secondary	DCR Assessed Centrally at Month 9	The DCR was defined as SD, PR or CR according to RECIST criteria v1.1. A second set of the original computed tomography (CT) scan images were used for a centralized RECIST v1.1 assessment by an independent radiologist.	Up to Month 9
Secondary	Median Progression Free Survival (PFS) Assessed Locally and Centrally	The PFS was defined as the time from the first treatment administration to disease progression according to RECIST criteria v 1.1 or death from any cause. The PFS was assessed locally by the investigator and centrally by an independent radiologist. The distribution of PFS times was estimated using the Kaplan-Meier method. The PFS of participants who were lost to follow-up and those who had not progressed at end of study were censored at the date of the last disease assessment.	From Day 1 up to end of study, 52 weeks
Secondary	Median Time to Response (TTR) Assessed Locally and Centrally	The TTR was defined as the time from first treatment administration to the first objective tumor response (PR or CR according to RECIST criteria v 1.1). The TTR was assessed locally by the investigator and centrally by an independent radiologist. The distribution of TTR was estimated using the Kaplan-Meier method. The TTR of participants who were lost to follow-up or died prior to any objective tumor response were censored at the date of the last disease assessment.	From Day 1 up to end of study, 52 weeks
Secondary	Median Duration of Response (DOR) Assessed Locally and Centrally	The DOR was defined as the time from onset of the first objective tumor response (PR or CR) to objective tumor progression (PD) according to RECIST criteria v 1.1. The DOR was assessed locally by the investigator and centrally by an independent radiologist.	From Day 1 up to end of study, 52 weeks
Secondary	Median Time to Progression (TTP) Assessed Locally and Centrally	The TTP was defined as the time from first treatment administration to the first objective tumor progression (PD) according to RECIST criteria v 1.1. The TTP was assessed locally by the investigator and centrally by an independent radiologist. The distribution of TTP times was estimated using the Kaplan-Meier method. The TTP of participants who were lost to follow-up, and those who had not progressed at end of study were censored at the date of the last disease assessment.	From Day 1 up to end of study, 52 weeks
Secondary	Best Overall Response (BOR) Assessed Locally and Centrally	The BOR was defined as the highest OR achieved by the participant from the time of first treatment until disease progression/recurrence or the end of study according to RECIST criteria v1.1 and was classified as: CR > PR > Non-CR/Non-progressive disease (NCR/NPD) > SD > PD > ND > not evaluable (NE). The BOR was assessed locally by the investigator and centrally by an independent radiologist. Percentages are based on the number of participants in the ITT/Safety population with non-missing observations.	From Day 1 up to end of study, 52 weeks
Secondary	Objective Response Rate (ORR) Assessed Locally and Centrally at Months 9 and 12	The ORR was defined as the percentage of participants with CR or PR according to RECIST criteria v1.1. The ORR was assessed locally by the investigator and centrally by an independent radiologist. The ORR was based on the participants with PD prior to 9 and 12 months with respectively PD at 9 and 12 months, and participants withdrawn before the assessment for reason other than PD or missing as failures.	Months 9 and 12
Secondary	DCR Assessed Locally and Centrally at Month 12	The DCR was defined as SD, PR or CR according to RECIST criteria v1.1. The DCR was assessed locally by the investigator and centrally by an independent radiologist.	Month 12
Secondary	DCR Assessed Locally and Centrally at Month 9 by Carcinoid Type	The influence of type of carcinoid [typical, atypical and undetermined carcinoid neuroendocrine tumors (NET)] on the local and central DCR at 9 months was analysed. Typical carcinoids were defined with absent foci of necrosis and mitotic count < 2 mitoses/2 millimeters^2 (mm^2); atypical carcinoids were defined with presence of foci of necrosis and/or 2 mitoses/2 mm^2 <= mitotic count <= 10 mitoses/2 mm^2; and carcinoid NET were defined as confirmed carcinoid without foci of necrosis and/or mitotic count reported. The DCR was assessed locally by the investigator and centrally by an independent radiologist.	Up to Month 9
Secondary	Percentage of Biochemical Responders According to Chromogranin A (CgA) Plasma Levels	Participants with baseline CgA plasma levels greater than the upper limit of normal (ULN) were assessed for a biochemical response. A biochemical responder was defined as a participant who had a decrease of CgA >= 50% compared to baseline, while biochemical SD was defined as a decrease < 50% or an increase <= 25% compared to baseline. Biochemical non-responders had an increase >25% compared to baseline. Baseline was defined as value at Day 1.	Baseline (Day 1) and Week 4, 12, 24, 36 and 52
Secondary	Neuron-Specific Enolase (NSE) and CgA Biomarker Levels	The NSE and CgA levels were classified according to ULN as follows: < 1 ULN, 1-2 ULN and > 2 ULN. Baseline was defined as value at Day 1. Percentages are based on the number of participants in the ITT/Safety population who attended the visit with non-missing observations.	Baseline and Weeks 4, 12, 24, 36 and 52
Secondary	Influence of Biomarkers Expression on Locally and Centrally Assessed PFS	The following biomarkers were investigated: Immunohistochemistry assay human somatostatin receptors 2 (SSTR2) including human epidermal growth factor receptor 2 (HER-2) score [0, 1+, 2+, 3+ and positive (+ve) versus negative (-ve)]; hormone receptor score (H-score) (from 0 to 300 as quantitative variable and +ve versus -ve); immunoreactive score (IRS) score (from 0 to 12 and reference for hazard ratio was 0-1). Ki67 index (from 0% to 100% and reference for hazard ratio was 4%-25%). O^6-methylguanine-DNA methyltransferase (MGMT) expression including percentage of +ve nuclei stained and methylated sites and H-score (from 0 to 300 as quantitative variable). For all these categories, higher score indicates a higher expression of biomarkers. Carcinoid type (typical or NET) was also investigated. Prognostic value of biomarkers expression at screening on PFS were assessed locally and centrally using univariate cox proportional hazard models.	From Screening period (-4 weeks) up to Week 52
Secondary	Influence of Biomarkers Expression on Locally and Centrally Assessed ORR at Months 9 and 12	The following biomarkers were investigated: Immunohistochemistry assay SSTR2 including HER-2 score (0, 1+, 2+, 3+); H-score (from 0 to 300 as quantitative variable); IRS score (from 0 to 12). Ki67 index (from 0% to 100%). MGMT expression including percentage of +ve nuclei stained and methylated sites and H-score (from 0 to 300 as quantitative variable). For all these categories, higher score indicates a higher expression of biomarkers. Less than 5 OR (CR or PR) events were reported, therefore this analysis was not performed.	Screening period, Months 9 and 12
Secondary	Influence of Biomarkers Expression on Locally and Centrally Assessed DCR at Months 9 and 12	The following biomarkers were investigated: Immunohistochemistry assay SSTR2 including HER-2 score (0, 1+, 2+, 3+ and +ve versus -ve); H-score (from 0 to 300 as quantitative variable and +ve versus -ve); IRS score (from 0 to 12 and reference for odds ratio was 0-1). Ki67 index (from 0% to 100% and reference for odds ratio was 4%-25%). MGMT expression including percentage of +ve nuclei stained and methylated sites and H-score (from 0 to 300 as quantitative variable). For all these categories, higher score indicates a higher expression of biomarkers. Carcinoid type (typical or NET) was also investigated. Prognostic value of biomarkers expression at screening on DCR were assessed locally and centrally using univariate logistic regression models.	Screening period, Months 9 and 12
Secondary	Coefficient of Agreement Between Central and Local Assessment of Tumor Radiological Response at Month 9	Differences between central radiology review and local investigator review were assessed according to the DCR status and the number of agreements and disagreements between the evaluators (central versus local) along with the p-values from the kappa test. A kappa statistic was used to evaluate the concordance between the central and the local review.	Month 9